This company has been marked as potentially delisted and may not be actively trading. Proteon Therapeutics (PRTO) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock PRTO vs. CDTX, CADL, GLUE, SLDB, OCGN, TVGN, CRDF, PROK, GNFT, and FENCShould you be buying Proteon Therapeutics stock or one of its competitors? The main competitors of Proteon Therapeutics include Cidara Therapeutics (CDTX), Candel Therapeutics (CADL), Monte Rosa Therapeutics (GLUE), Solid Biosciences (SLDB), Ocugen (OCGN), Tevogen Bio (TVGN), Cardiff Oncology (CRDF), ProKidney (PROK), Genfit (GNFT), and Fennec Pharmaceuticals (FENC). These companies are all part of the "medical" sector. Proteon Therapeutics vs. Its Competitors Cidara Therapeutics Candel Therapeutics Monte Rosa Therapeutics Solid Biosciences Ocugen Tevogen Bio Cardiff Oncology ProKidney Genfit Fennec Pharmaceuticals Cidara Therapeutics (NASDAQ:CDTX) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings. Does the media refer more to CDTX or PRTO? In the previous week, Cidara Therapeutics had 4 more articles in the media than Proteon Therapeutics. MarketBeat recorded 4 mentions for Cidara Therapeutics and 0 mentions for Proteon Therapeutics. Cidara Therapeutics' average media sentiment score of 0.23 beat Proteon Therapeutics' score of 0.00 indicating that Cidara Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cidara Therapeutics Neutral Proteon Therapeutics Neutral Do insiders & institutionals have more ownership in CDTX or PRTO? 35.8% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 23.0% of Proteon Therapeutics shares are owned by institutional investors. 3.9% of Cidara Therapeutics shares are owned by insiders. Comparatively, 45.7% of Proteon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is CDTX or PRTO more profitable? Proteon Therapeutics has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. Proteon Therapeutics' return on equity of 0.00% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cidara Therapeutics-289.05% -69.64% -33.73% Proteon Therapeutics N/A N/A -118.68% Which has more risk & volatility, CDTX or PRTO? Cidara Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Proteon Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Which has preferable earnings & valuation, CDTX or PRTO? Proteon Therapeutics has lower revenue, but higher earnings than Cidara Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCidara Therapeutics$302K948.92-$22.93M-$29.47-0.78Proteon TherapeuticsN/AN/A-$20.73M-$1.15-2.73 Does the MarketBeat Community believe in CDTX or PRTO? Cidara Therapeutics received 194 more outperform votes than Proteon Therapeutics when rated by MarketBeat users. Likewise, 70.61% of users gave Cidara Therapeutics an outperform vote while only 69.21% of users gave Proteon Therapeutics an outperform vote. CompanyUnderperformOutperformCidara TherapeuticsOutperform Votes46670.61% Underperform Votes19429.39% Proteon TherapeuticsOutperform Votes27269.21% Underperform Votes12130.79% Do analysts prefer CDTX or PRTO? Cidara Therapeutics currently has a consensus target price of $42.00, suggesting a potential upside of 83.89%. Given Cidara Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Cidara Therapeutics is more favorable than Proteon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Proteon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCidara Therapeutics beats Proteon Therapeutics on 13 of the 18 factors compared between the two stocks. Get Proteon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTO vs. The Competition Export to ExcelMetricProteon TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.64M$3.09B$5.57B$8.50BDividend YieldN/A1.56%5.27%4.17%P/E Ratio-2.7332.6326.7519.65Price / SalesN/A455.18403.98152.07Price / CashN/A168.6838.2534.64Price / Book-52.333.366.964.59Net Income-$20.73M-$72.35M$3.23B$248.23M Proteon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTOProteon TherapeuticsN/A$3.14-3.7%N/A+22.2%$69.64MN/A-2.7317CDTXCidara Therapeutics4.1005 of 5 stars$23.30+2.8%$41.86+79.6%+69.9%$292.35M$302K-0.9190Analyst ForecastCADLCandel Therapeutics3.0119 of 5 stars$5.75+2.9%$21.00+265.2%-29.6%$288.09M$120K-3.3260GLUEMonte Rosa Therapeutics2.292 of 5 stars$4.64+3.1%$15.50+234.1%+28.2%$285.41M$159.49M-2.5490SLDBSolid Biosciences3.8647 of 5 stars$3.50-1.1%$14.90+325.7%-42.9%$271.30M$8.09M-1.15100Positive NewsAnalyst RevisionGap DownOCGNOcugen1.5599 of 5 stars$0.85+1.7%$6.00+604.6%-20.4%$248.69M$4.52M-4.7380Positive NewsTVGNTevogen Bio4.0975 of 5 stars$1.28-0.8%$7.10+454.7%+49.9%$235.38MN/A0.003Analyst ForecastCRDFCardiff Oncology1.6572 of 5 stars$3.51+4.8%$12.00+241.9%+41.1%$233.51M$587K-3.7320Gap UpPROKProKidney2.4135 of 5 stars$0.78+4.5%$5.00+541.7%-69.3%$228.07M$306K-1.423Positive NewsGap UpGNFTGenfit2.5349 of 5 stars$4.51+5.4%$13.00+188.2%+0.2%$225.48M$67.00M0.00120Positive NewsShort Interest ↓FENCFennec Pharmaceuticals2.7984 of 5 stars$7.88-0.6%$13.00+65.0%+17.3%$217.64M$30.91M-78.79N/APositive News Related Companies and Tools Related Companies Cidara Therapeutics Alternatives Candel Therapeutics Alternatives Monte Rosa Therapeutics Alternatives Solid Biosciences Alternatives Ocugen Alternatives Tevogen Bio Alternatives Cardiff Oncology Alternatives ProKidney Alternatives Genfit Alternatives Fennec Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTO) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRTO Stock Free PRTO Stock Alerts